Erratum: Epperla N, Maddocks KJ, Salhab M, et al. C‐MYC–positive relapsed and refractory, diffuse large B‐cell lymphoma: Impact of additional “hits” and outcomes with subsequent therapy. Cancer. 2017;123:4411‐4418.

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|124|4|867-867

ISSN： 0008-543x

Source： CANCER, Vol.124, Iss.4, 2018-02, pp. : 867-867

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

A phase II trial of AZD1152 in relapsed/refractory diffuse large B‐cell lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 6, 2015-09 ,pp. : 886-890

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rituximab in Combination with Interferon-Alpha in Relapsed and Refractory Diffuse Large B-Cell Non-Hodgkin’s Lymphoma

By  

Acta Haematologica, Vol. 106, Iss. 3, 2001-11 ,pp. : 141-142

Karger

Access to resources Recommend Favorite

Radiation for diffuse large B‐cell lymphoma in the rituximab era: Analysis of the National Comprehensive Cancer Network lymphoma outcomes project

By  

CANCER, Vol. 121, Iss. 7, 2015-04 ,pp. : 1032-1039

John Wiley & Sons Inc

Access to resources Recommend Favorite

Excellent outcomes and lack of prognostic impact of cell of origin for localized diffuse large B‐cell lymphoma in the rituximab era

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 5, 2015-12 ,pp. : 776-783

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinicopathologic Characteristics of CD99-Positive Diffuse Large B-Cell Lymphoma

By  

Acta Haematologica, Vol. 125, Iss. 3, 2010-12 ,pp. : 167-174

Karger

Access to resources Recommend Favorite